The role of telomerase reverse transcriptase (TERT) promoter mutations in prognosis in bladder cancer

References

• Günes C, Rudolph KL. The role of telomeres in stem cells and cancer. Cell. 2013;152(3):390–393.
   PubMed Web of Science ®Google Scholar
• Kyo S, Takakura M, Fujiwara T, et al. Understanding and exploiting hTERT promoter regulation for diagnosis and treatment of human cancers. Cancer Sci. 2008;99(8):1528–1538.
   PubMed Web of Science ®Google Scholar
• Popli DB, Sircar K, Chowdhry A. Telomerase: an exploration toward the end of cancer. Indian J Dent Res Official Publication of Indian Soc Dental Res. 2017;28(5):574–584.
   PubMedGoogle Scholar
• Cong YS. The human telomerase catalytic subunit hTERT: organization of the gene and characterization of the promoter. Hum Mol Genet. 1999;8(1):137–142.
   PubMed Web of Science ®Google Scholar
• Vinagre J, Almeida A, Pópulo H, et al. Frequency of TERT promoter mutations in human cancers. Nat Commun. 2013;4(1):2185. .
   PubMedGoogle Scholar
• Rachakonda PS, Hosen I, De Verdier PJ, et al. TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism. Proc Natl Acad Sci USA. 2013;110(43):17426–17431.
   PubMed Web of Science ®Google Scholar
• Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009;6(7):e1000100.
   PubMed Web of Science ®Google Scholar
• Van Rhijn BWG, Hentschel AE, Bründl J, et al. Prognostic Value of the WHO1973 and WHO2004/2016 classification systems for grade in primary ta/t1 non-muscle-invasive bladder cancer: a multicenter European Association of urology non-muscle-invasive bladder cancer guidelines panel study.European Urology Oncology 2021.
   Web of Science ®Google Scholar
• Bouwmeester W, Zuithoff NP, Mallett S, et al. Reporting and methods in clinical prediction research: a systematic review. PLoS Med. 2012;9(5):1–12.
   PubMed Web of Science ®Google Scholar
• Williamson PR, Smith CT, Hutton JL, et al. Aggregate data meta-analysis with time-to-event outcomes. Stat Med. 2002;21(22):3337–3351.
   PubMed Web of Science ®Google Scholar
• Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998;17(24):2815–2834.
   PubMed Web of Science ®Google Scholar
• Tierney JF, Stewart LA, Ghersi D, et al. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8(1):16.
   PubMed Web of Science ®Google Scholar
• Batista R, Lima L, Vinagre J, et al. TERT promoter mutation as a potential predictive biomarker in BCG-treated bladder cancer patients. Int J Mol Sci. 2020;21(3):3.
   Web of Science ®Google Scholar
• Critelli R, Fasanelli F, Oderda M, et al. Detection of multiple mutations in urinary exfoliated cells from male bladder cancer patients at diagnosis and during follow-up. Oncotarget. 2016;7(41):67435–67448. .
   PubMedGoogle Scholar
• Descotes F, Kara N, Decaussin-Petrucci M, et al. Non-invasive prediction of recurrence in bladder cancer by detecting somatic TERT promoter mutations in urine. Br J Cancer. 2017;117(4):583–587.
   PubMed Web of Science ®Google Scholar
• Hayashi Y, Fujita K, Matsuzaki K, et al. Clinical Significance of Hotspot Mutation Analysis of Urinary Cell-Free DNA in Urothelial Bladder Cancer. Front Oncol. 2020;10:755.
   PubMed Web of Science ®Google Scholar
• Hayashi Y, Fujita K, Nojima S, et al. TERT C228T mutation in non-malignant bladder urothelium is associated with intravesical recurrence for patients with non-muscle invasive bladder cancer. Mol Oncol. 2020;14(10):2375–2383.
   PubMed Web of Science ®Google Scholar
• Leão R, Lee D, Figueiredo A, et al. Combined genetic and epigenetic alterations of the TERT promoter affect clinical and biological behavior of bladder cancer. Int J Cancer. 2019;144(7):1676–1684.
   PubMed Web of Science ®Google Scholar
• Roggisch J, Ecke T, Koch S. Molecular identification of telomerase reverse transcriptase (TERT) promotor mutations in primary and recurrent tumors of invasive and noninvasive urothelial bladder cancer. Urol Oncol. 2020;38(3):77.e17–77.e25.
   PubMed Web of Science ®Google Scholar
• Grotenhuis AJ, Dudek AM, Verhaegh GW, et al. Independent replication of published germline polymorphisms associated with urinary bladder cancer prognosis and treatment response. Bladder Cancer (Amsterdam Netherlands). 2016;2(1):77–89.
   PubMed Web of Science ®Google Scholar
• Ferlay J, Colombet M, Soerjomataram I, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019;144(8):1941–1953.
   PubMed Web of Science ®Google Scholar
• Van Rhijn BW, Burger M, Lotan Y, et al. Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. Eur Urol. 2009;56(3):430–442.
   PubMed Web of Science ®Google Scholar
• Netto GJ. Molecular biomarkers in urothelial carcinoma of the bladder: are we there yet? Nat Rev Urol. 2011;9(1):41–51.
   PubMed Web of Science ®Google Scholar
• Hosen I, Rachakonda PS, Heidenreich B, et al. Mutations in TERT promoter and FGFR3 and telomere length in bladder cancer. Int J Cancer. 2015;137(7):1621–1629.
   PubMed Web of Science ®Google Scholar
• Gourd E. TERT mutations in urine could predict bladder cancer recurrence. Lancet Oncol. 2017;18(8):e443.
   PubMed Web of Science ®Google Scholar
• Jin A, Xu J, Wang Y. The role of TERT promoter mutations in postoperative and preoperative diagnosis and prognosis in thyroid cancer. Medicine (Baltimore). 2018;97(29):e11548.
   PubMed Web of Science ®Google Scholar
• Sk O, Ms C, Mh P, et al. TERT promoter mutated circulating tumor DNA as a biomarker for prognosis in hepatocellular carcinoma. Scand J Gastroenterol. 2020;55(12):1433–1440.
   PubMed Web of Science ®Google Scholar
• Blateau P, Coyaud E, Laurent E, et al. TERT promoter mutation as an independent prognostic marker for poor prognosis MAPK inhibitors-treated melanoma. Cancers (Basel). 2020;12(8):8.
   Web of Science ®Google Scholar
• Allory Y, Beukers W, Sagrera A, et al. Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome. Eur Urol. 2014;65(2):360–366.
   PubMed Web of Science ®Google Scholar
• Russo IJ, Ju Y, Gordon NS, et al. Toward personalised liquid biopsies for urothelial carcinoma: characterisation of ddPCR and urinary cfDNA for the detection of the TERT 228 G>A/T mutation. Bladder Cancer (Amsterdam, Netherlands). 2018;4(1):41–48.
   PubMed Web of Science ®Google Scholar
• Bournaud C, Descotes F, Decaussin-Petrucci M, et al. TERT promoter mutations identify a high-risk group in metastasis-free advanced thyroid carcinoma. Eur J Cancer (Oxford England 1990). 2019;108:41–49.
   PubMed Web of Science ®Google Scholar
• Griewank KG, Murali R, Puig-Butille JA, et al. TERT promoter mutation status as an independent prognostic factor in cutaneous melanoma. J Natl Cancer Inst. 2014;106:9.
   Google Scholar
• Bryan C, Rice C, Hoffman H, et al. Structural basis of telomerase inhibition by the highly specific BIBR1532. Structure. 2015;23(10):1934–1942.
   PubMed Web of Science ®Google Scholar
• Ruden M, Puri N. Novel anticancer therapeutics targeting telomerase. Cancer Treat Rev. 2013;39(5):444–456.
   PubMed Web of Science ®Google Scholar
• Asai A, Oshima Y, Yamamoto Y, et al. A novel telomerase template antagonist (GRN163) as a potential anticancer agent. Cancer Res. 2003;63(14):3931–3939.
   PubMed Web of Science ®Google Scholar